

500941
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/064467 A1

- (51) International Patent Classification⁷: **C07K 14/47**, A61K 38/17
- (21) International Application Number: PCT/SE03/00139
- (22) International Filing Date: 28 January 2003 (28.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0200265-7 29 January 2002 (29.01.2002) SE
60/377,349 30 April 2002 (30.04.2002) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **BIOVITRUM AB** [SE/SE]; S-112 76 Stockholm (SE).
- Published:
— with international search report
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CLIMENT-JOHANSSON, Isabel** [ES/SE]; Odengatan 70, 2tr, S-113 22 Stockholm (SE). **ENERBÄCK, Sven** [SE/SE]; Slätthultsliden 13 A, S-431 69 Mölndal (SE).
- (74) Agent: **HÖGLUND, Lars**; Biovitrum AB, S-112 76 Stockholm (SE).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: A COMPLEX OF A HUMAN FOXC2 PROTEIN AND A FOXC2-INTERACTING PROTEIN

(57) Abstract: The present invention relates to complexes of the FOXC2 protein with other proteins, in particular complexes of FOXC2 with proteins designated p621, NOLP, HSC71, FTP3, CLH1, and Kinase A Anchor Protein 84/149 (AKAP). The protein complexes can be used in methods of identifying agents useful for the treatment of medical conditions that can be treated by modulated FOXC2 activity, such as obesity, hypertriglyceridemia, diet-induced insulin resistance, and/or type 2 diabetes.

WO 03/064467 A1

A complex of a human FOXC2 protein and a FOXC2-interacting protein

TECHNICAL FIELD

The present invention relates to complexes of the FOXC2 protein with other proteins, in particular complexes of FOXC2 with proteins designated p621, NOLP,
5 HSC71, FTP3, CLH1, and Kinase A Anchor Protein 84/149 (AKAP). The complexes can be used in methods of identifying agents useful for the treatment of medical conditions which can be treated by modulated FOXC2 activity, such as obesity, hypertriglyceridemia, diet-induced insulin resistance, and/or type 2 diabetes.

BACKGROUND ART

Obesity, hyperlipidemia, and insulin resistance are common forerunners of type 2 diabetes mellitus. The human winged helix/forkhead transcription factor gene FOXC2 has been identified as a key regulator of adipocyte metabolism (Cederberg, A. et al. (2001) Cell 106:563-573). Increased FOXC2 expression, in adipocytes, has a
15 pleiotropic effect on gene expression, which leads to a lean and insulin sensitive phenotype. FOXC2 affects adipocyte metabolism by increasing the sensitivity of the beta-adrenergic-cAMP-protein kinase A (PKA) signaling pathway through alteration of adipocyte PKA holoenzyme composition. Increased FOXC2 levels, induced by high fat diet, seem to counteract most of the symptoms associated with obesity, including
20 hypertriglyceridemia and diet-induced insulin resistance; a likely consequence hereof would be protection against type 2 diabetes.

The nucleotide and amino acid sequences of the human FOXC2 protein (SEQ ID NO:1), also known as FKHL14, FREAC-11, or S12, as well as the corresponding mouse mesenchyme forkhead-1 (MFH-1) protein, are known in the art, see Miura, N. et
25 al. (1993) FEBS letters 326: 171-176; Miura, N. et al. (1997) Genomics 41: 489-492; WO 98/54216 and WO 01/60853.

Various mechanisms have been proposed for how FOXC2 function to regulate gene expression. One possibility is that FOXC2 interact with factors that are downstream of the Notch-Delta signaling pathway (Kume, T. et al. (2001) Genes &
30 Development 15:2470-2482). For example, Groucho proteins form transcription repression complexes with bHLH transcriptions factors. It has been shown that Groucho can bind to two FOX proteins, FOXG1 and FOXA2 (Wang, J.-C. et al. (2001) J. Biol. Chem. 275: 18418-18423; Yao, J. et al. (2001) Mol. Cell. Biol. 21:1962-1972), and it

was suggested that similar kinds of interactions may occur with FOXC proteins (Kume et al., *supra*). However, an interaction between the FOXC2 protein and Groucho has not previously been demonstrated. Further, interactions of FOXC2 with any of the proteins designated p621, NOLP, Heat Shock Cognate Protein-71 (HSC71), FTP3, CLH1, or Kinase A Anchor Protein 84/149 (AKAP) have not been previously described.

DISCLOSURE OF THE INVENTION

The present invention is based upon the identification of proteins that interact with FOXC2. The identification of FOXC2-interacting proteins contributes to the understanding of this transcription factor-signaling pathway. Further, such interacting proteins can themselves be useful for the identification of agents useful for the treatment of obesity and diabetes.

Consequently, in a first aspect this invention provides a protein complex of a FOXC2 protein, e.g., a human FOXC2 protein, and a FOXC2-interacting protein, wherein the FOXC2-interacting protein contains an amino acid sequence selected from the group consisting of p621 (e.g., SEQ ID NO:2), NOLP (e.g., SEQ ID NO:3), Heat Shock Cognate Protein-71 (HSC71; e.g., SEQ ID NO:4), FTP3 (e.g., SEQ ID NO:5), CLH1 (e.g., SEQ ID NO:6), and Kinase A Anchor Protein 84/149 (AKAP; e.g., SEQ ID NO:7).

In one embodiment, the invention features a substantially pure protein complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the amino acid sequence of SEQ ID NO:1 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7.

In some embodiments the first polypeptide comprises a sequence that differs from the amino acid sequence of SEQ ID NO:1 at one or more residues. In addition, in some embodiments the second polypeptide comprises a sequence that differs from the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7 at one or more residues. The differences are, preferably, differences or changes at a non-essential residue or a conservative substitution. In one embodiment, the first or second polypeptide includes an amino acid sequence at least about 60% identical to a sequence shown as SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, or a fragment thereof. Preferably, the polypeptide is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to SEQ ID NO:1, 2, 3, 4, 5, 6, or 7. Preferred polypeptide fragments are at least 10%, preferably at least

20%, 30%, 40%, 50%, 60%, 70%, or more, of the length of the sequence shown as SEQ ID NO:1, 2, 3, 4, 5, 6, or 7. The first polypeptide preferably retains the ability to bind to the polypeptide of any of SEQ ID NO:2, 3, 4, 5, 6, or 7. In some examples, the first polypeptide has FOXC2 transcriptional activity. The second polypeptide preferably
5 retains the ability to bind to the polypeptide of SEQ ID NO:1.

The term "substantially pure" as used herein in reference to a given protein complex or polypeptide means that the protein complex or polypeptide is substantially free from other biological macromolecules. For example, the substantially pure protein complex or polypeptide is at least 25%, 50, 75, 80, 85, 95, or 99% pure by dry weight.
10 Purity can be measured by any appropriate standard method known in the art, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

In another aspect, the invention provides a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a complex of a
15 human FOXC2 protein and a FOXC2-interacting protein, wherein the FOXC2-interacting protein has an amino acid sequence chosen from the group consisting of SEQ ID NO:2, 3, 4, 5, 6, 7 or 8, and a pharmaceutically acceptable carrier.

Another embodiment of the invention is a pharmaceutical composition for use in the treatment of a medical condition which is treatable by modulated FOXC2 activity, comprising a therapeutically or prophylactically effective amount of a FOXC2-
20 interacting protein having an amino acid sequence chosen from the group consisting of SEQ ID NO:2, 3, 4, 5, 6, 7 or 8, and a pharmaceutically acceptable carrier.

Another embodiment of the invention is a pharmaceutical composition comprising an amount of a protein complex described herein effective for the treatment
25 or prevention of a medical condition associated with FOXC2 expression or activity, and a pharmaceutically acceptable carrier.

Yet another aspect of the invention is a method of modulating FOXC2 expression or activity, the method comprising contacting a cell expressing FOXC2, e.g., human FOXC2, with an amount of a polypeptide, e.g., a substantially pure polypeptide,
30 described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7), or a nucleic acid encoding the polypeptide, sufficient to modulate the expression or activity of FOXC2 in the cell.

A further aspect of the invention is a method for the treatment or prophylaxis of a medical condition treatable by modulated FOXC2 activity, the method comprising

administering to a patient in need of such treatment or prophylaxis an amount of a polypeptide, e.g., a substantially pure polypeptide, described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7) effective to treat or prevent a medical condition treatable by modulated FOXC2 activity, and a

5 pharmaceutically acceptable carrier

The medical condition can be a medical condition that is putatively treatable by increased FOXC2 activity, such as obesity, hypertriglyceridemia, diet-induced insulin resistance, or type 2 diabetes. Alternatively, the medical condition can be a medical condition that is putatively treatable by decreased FOXC2 activity, such as anorexia.

10 The term "treatment" means any treatment of a diseases in a mammal, including:

(i) preventing the disease, i.e. causing the clinical symptoms of the disease not to develop (prophylaxis); (ii) inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or (iii) relieving the disease, i.e. causing the regression of clinical symptoms. The term "effective amount" means a dosage sufficient to provide

15 treatment for the disease state being treated. This will vary depending on the patient, the disease and the treatment being effected.

In another aspect, the invention features a method of identifying an agent that modulates (increases or decreases) the formation of a FOXC2 protein complex, the method comprising: (i) contacting a first polypeptide described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:1) and a second polypeptide described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7) in the presence of a candidate agent; (ii) measuring the formation of a complex between the first polypeptide and the second polypeptide in the presence of the candidate agent; and (iii) comparing the formation of the complex between the first polypeptide and the second polypeptide in the presence of the candidate agent with the formation of a complex between the first polypeptide and the second polypeptide in the absence of the candidate agent, to thereby determine whether the candidate agent modulates the formation of a FOXC2 protein complex.

25 The invention also features a method of identifying an agent that modulates a FOXC2 activity, the method comprising: (i) contacting a first polypeptide described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:1) and a second polypeptide described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7) in the presence of a candidate agent; (ii) measuring a FOXC2 activity of the first polypeptide in the presence of the candidate

agent; and (iii) comparing the FOXC2 activity of the first polypeptide in the presence of the candidate agent with the FOXC2 activity of the first polypeptide in the absence of the candidate agent, to thereby determine whether the candidate agent modulates a FOXC2 activity.

5 The invention also features a method of identifying an agent that modulates a FOXC2 activity, the method comprising: (i) contacting a first polypeptide described herein (e.g., a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7) with a candidate agent; (ii) determining that the candidate agent binds to the first polypeptide; (iii) contacting a second polypeptide described herein (e.g., a
10 polypeptide comprising the amino acid sequence of SEQ ID NO:1) with the candidate agent; (iv) measuring a FOXC2 activity of the second polypeptide in the presence of the candidate agent; and (v) comparing the FOXC2 activity of the second polypeptide in the presence of the candidate agent with the FOXC2 activity of the second polypeptide in the absence of the candidate agent, to thereby determine whether the candidate agent
15 modulates a FOXC2 activity.

 The first polypeptide and/or the second polypeptide used in the methods can optionally be a substantially pure polypeptide. The methods of the invention can be carried out using a cell-based system or in a cell-free system. An example of a FOXC2 activity that can be measured in the methods of the invention is a FOXC2
20 transcriptional activity.

 The invention also provides a method for the treatment or prophylaxis of a medical condition treatable by modulated FOXC2 activity, the method comprising administering to a patient in need of such treatment or prophylaxis an amount of an agent identified by a method described herein that is effective to treat or prevent a
25 medical condition treatable by modulated FOXC2 activity, and a pharmaceutically acceptable carrier.

 The medical condition can be a medical condition that is putatively treatable by increased FOXC2 activity, such as obesity, hypertriglyceridemia, diet-induced insulin resistance, or type 2 diabetes. Alternatively, the medical condition can be a medical
30 condition that is putatively treatable by decreased FOXC2 activity, such as anorexia.

 In a further aspect, the invention provides antibodies directed against a complex of a human FOXC2 protein and a FOXC2-interacting protein, which complex is defined above according to the invention. Such antibodies can be prepared according to methods well known in the art. The said antibodies are useful e.g. in methods for the

characterization and/or purification of the human FOXC2 protein and/or a FOXC2-interacting protein wherein a specific binding of the antibody to the said complex are utilized. Such methods can include e.g. immunoprecipitation, immunoblotting, or immunoaffinity chromatography. Immunoprecipitation consists on a multiple ordered

5 steps including cells lysis, binding of a specific antigen to an antibody, precipitation of the antigen-antibody complex, washing and dissociation of the antigen from the immune complex (Current Protocols in Molecular Biology, Chapter 10: Analysis of Proteins, 1991, John Wiley & Sons, Inc.) Immunoblotting is a method that combines the resolution of gel electrophoresis with the specificity of immunochemical detection.

10 Immunoblotting can be used to determine a number of important characteristics of protein antigen (i.e., the presence and quantity on a sample, molecular weight, etc.). It can be combined with immunoprecipitation to allow a very sensitive detection of minor antigens and to study specific interactions between antigens (Antibodies, A Laboratory Manual, Chapter 12: Immunoblotting, 1998, Harlow & Lane, CSH). Immunoaffinity

15 chromatography enables for the purification of soluble or membrane-bound protein antigens from cells or homogenized tissues. The technique involves the elution of a single protein from an immunoaffinity column after prior elution of nonspecific absorbed proteins (Current Protocols in Protein Science, Chapter 9: Affinity purification, 1996, John Wiley & Sons, Inc.).

20 In one embodiment, the invention features a method for purifying a FOXC2-interacting protein, the method comprising: (i) contacting a protein complex comprising a FOXC2 protein comprising the amino acid sequence of SEQ ID NO:1 and a FOXC2-interacting protein comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, 7 or 8 with an antibody that binds to the protein complex; and (ii) purifying the

25 FOXC2-interacting protein from the protein complex. An antibody that binds to the protein complex can also be used to purify the protein complex and/or the FOXC2 protein. Any of the first and/or second polypeptides described herein can be used in the antibody-based purification methods of the invention.

Throughout this description the terms "standard protocols" and "standard

30 procedures", when used in the context of molecular biology techniques, are to be understood as protocols and procedures found in an ordinary laboratory manual such as: Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994, or Sambrook, J., Fritsch, E.F. and Maniatis, T., Molecular Cloning: A

laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Suitable methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Below, the invention is described in the appended examples, which are intended to illustrate the invention, without limiting the scope of protection.

EXAMPLES

EXAMPLE 1: Identification of putative positive FOXC2 interacting clones by SRS yeast two-hybrid system

1.1. Overview of the Sos Recruitment System (SRS)

The Sos Recruitment System (SRS) was used to assay for polypeptides interacting with the human FOXC2 polypeptide. SRS is a modification of the well-known yeast two-hybrid system first described by Fields & Song (1989) Nature 340, 245-246.

In the CytoTrap® SRS

(http://www.stratagene.com/vectors/signal_trans/cytotrap; see also Aronheim, A. et al. (1997) Mol. Cell. Biol. 17:3094-3102; and US 5,776,689), proteins are expressed in the cytoplasm where, unlike in the nucleus, they may undergo posttranslational modifications. Protein-protein interactions in the cytoplasm are detected by recruitment of the human Sos gene product (hSos) to the membrane of the cell where it activates the Ras pathway. The CytoTrap system uses the unique yeast strain cdc25H, which contains a temperature-sensitive mutation in the cdc25 gene, the yeast homologue for hSos. This protein, a guanyl nucleotide exchange factor, is essential for activation of the Ras pathway and ultimately for the survival and growth of the cell. The mutation in the cdc25 protein is temperature sensitive; the cells can grow at 25°C but not at 37°C. This

cdc25 mutation can be complemented by the hSos gene product to allow growth at 37°, providing that the hSos protein is localized to the membrane via a protein-protein interaction.

The pMyr vector is designed for cDNA library construction. Genes are expressed in this vector as a fusion protein with the src myristylation signal that targets and anchors the protein to the cell membrane with the gene product extruding into the cytoplasm. Protein expression is controlled by the GAL1 promoter, which is induced in the presence of galactose but repressed in the presence of glucose.

The bait protein (FOXC2) is expressed as a fusion protein with the hSos protein from the pSos vector. When the cDNA library and the bait construct are cotransformed into the cdc25H yeast strain, the only cells capable of growing at 37°C on galactose medium are those that have been rescued by a protein-protein interaction recruiting hSos to the cell membrane.

1.2. Cloning of human FOXC2 in pSos

Human full-length FOXC2 (amino acids 1-501) from the pCB6+ plasmid (Cederberg, A. et al. (2001) Cell 106: 1-20) using CSIX-17 (SEQ ID NO:9) and CSIX-18 (SEQ ID NO:10) primers was amplified by PCR according to standard procedures. The amplified fragment was cloned into the pSos vector (Stratagene catalog No. 217433) using *Bam*HI sites included in the primers. The insert orientation was analyzed by restriction digestion, and the FOXC2 sequence was confirmed by nucleotide sequencing according to standard procedures.

1.3. Expression of pSos-FOXC2 in yeast

The yeast strain cdc25H (Stratagene catalog No. 217437) was transformed with pSos-FOXC2 according to the protocol (Stratagene; CytoTrap Vector Kit; catalog No. 217438) and plated on SD/PDO-Leu plates. Protein extracts were made as described (Moilanen A. et al. (1998) Mol. Cell Biol. 18: 5128-5139) and subsequently analyzed by PAGE and Western blotting using anti-mouse Sos antibodies (BD Transduction Laboratories; catalog No. S15520-050). The western blot analysis showed protein bands migrating with the expected molecular weight corresponding to Sos-FOXC2 (MW 178 kDa) and Sos (MW 127 kDa). Additional bands of lower molecular weight were observed, probably due to protein degradation occurring during extract preparation or in the yeast cells during growth.

1.4 Transformation of yeast cells

A human fetal brain cDNA library (Stratagene catalog No. 975204) was used for transformation of yeast cells. The library was amplified by plating approximately 5 200,000 colonies/plate of LB-Kan (14-cm diameter). Since the library titer was 0.3×10^9 cfu/ml a total 50 plates inoculated with 0.66 μ l of library suspension per plate were used. Cells were incubated overnight at 37°C and afterwards, colonies of a pinpoint size were harvested with 2x4 ml of LB using a sterile scraping glass. Additional LB-Kan medium was added to a final volume of 1,5 l. The cell suspension was incubated for 2 h 10 at 37°C. Cells were harvested by centrifugation at 6,000 x g for 10 min and the plasmid DNA was prepared using Plasmid Maxi Prep columns (Qiagen catalog No. 12162) following the QIAGEN protocol.

Transformation was performed as described by Stratagene (CytoTrap XR Library Construction Kit; Instruction Manual; catalog No. 200444), with the difference 15 that the transformation was sequential, i.e. carried out in two steps. First, yeast was transformed with the pSOS-FOXC2 plasmid. Cdc25H yeast cells carrying the pSos-FOXC2 plasmid were made competent and transformed with 80 μ g of cDNA library DNA. After 72 hours of growth at 25°C in glucose (–Leu –Ura) the plates were replicated into a galactose medium and incubated at 37°C for a maximum of 11 days. 20 Transformants were screened following Stratagene protocols for the revertants test.

Approximately 8×10^5 yeast transformants were screened and 4,000 galactose-dependent candidate clones were obtained. After a parallel growth test at non-permissive temperature in glucose and galactose media, 230 of these clones grew only in galactose and were analyzed further. Clones growing in both glucose and galactose 25 media were considered to be revertants and were therefore discarded.

EXAMPLE 2: Analysis of putative positive interacting clones

2.1. *Sequence analysis of putative FOXC2-interacting clones*

Total yeast DNA was prepared as described by Stratagene (CytoTrap XR Library Construction Kit; Instruction Manual; catalog No. 200444). The final pellet was 30 dissolved in 20 μ l H₂O and used as template for PCR amplification or transformation of *E. coli* cells. 40 μ l TOP10 7' electrocompetent cells were transformed (2.5 kV, 25 μ F and 200 Ω) with 2 μ l of this DNA. Immediately, 1 ml of SOC medium was added and

cells were incubated for 1 hour at 37°C. All cells were plated onto LB-plates containing 30 µg/ml of chloramphenicol. Transformants were used for plasmid DNA preparations (QIAGEN).

In order to amplify prey inserts the extracted yeast DNA was used as template.

- 5 The PCR reaction was set up by mixing 1 µl of desired yeast DNA, 1xPCR buffer, 5 units TaqPol, 40 pmol each of the primers NA15 (SEQ ID NO:11) and NA1149 (SEQ ID NO:12) and 200 µM dNTP's to a final volume of 50 µl. The following PCR reaction was started: 95°C for 5 minutes followed by 35 cycles consisting of 30 seconds at 95°C, 30 seconds at 55°C and 1.5 minute at 72°C and a final 7 minutes at 72°C. The
- 10 fragments obtained were purified and sequenced.

Sequence analysis was performed at the level of PCR or plasmid DNA by BLAST homology search against a non-redundant nucleotide database without ESTs (EMBL and GenBank).

15 2.2. Identification of seven FOXC2-interacting proteins

- Among the expected false positives, several clones encoding hSos, Ras, and other members of Ras-GTPase family were identified, confirming the ras-signaling pathway read-out for this assay. The remaining clones corresponded to previously characterized genes (139 clones) and unknown genes (16 clones). In both cases, some of
- 20 them were found several times as identical clones, probably due to library amplification. The unknown clones were analyzed further using the validation test in yeast described above. These clones were shown not to express proteins capable of specific interactions with FOXC2, and were therefore disregarded. The clones corresponding to known genes could be classified into the following protein categories: transcription regulators,
- 25 matrix proteins, transcription factors, kinase-subunits, and nuclear proteins. In total, 43 clones were identified as putative "hits" and further analyzed.

- In order to eliminate hits with a nonspecific interaction to FOXC2 (e.g. proteins interacting with the Sos tag-protein) the 43 identified clones were subjected to a false positive test. This was done by co-transformation of cdc25H yeast with each of the hit
- 30 proteins (pMyrHit) together with (a) pSos-FOXC2; (b) pSos; or (c) as a control, Sos fused to MafB (Stratagene; CytoTrap Vector Kit; catalog No. 217438). Cells that grew in galactose at 37°C only when transformed with plasmid (a) were considered to represent a true positive interaction. By this procedure, seven proteins (Table I) were

identified as putative FOXC2-interacting proteins. For these seven proteins, the above experiment was repeated also with Col1 (Stratagene; CytoTrap Vector Kit; catalog No. 217438) as a control, which gave the same results.

To characterize further the interactions between FOXC2 and FOXC2-interacting proteins in yeast, the interaction of Sos-FOXC2 hybrid protein was compared with the one between MafB proteins. MafB proteins are known to form dimers (Kataoka, K. et al. (1994) Mol. Cell. Biol. 14: 7581-7591). The p621 gene exhibited the strongest interaction to FOXC2 followed by FTP3, Groucho and Clathrin. A weaker interaction was observed for PKA anchor protein, NOLP and HSC71.

TABLE I lists putative FOXC2-interacting proteins identified by SRS. Interaction strength is determined relative to the interaction between MafB proteins (+++++) during the same conditions.

TABLE I

Gene	SEQ ID NO:	Accession No.	Interaction strength
p621	2	AJ242978 (partial mRNA)	++++
NOLP	3	AB017800	+
HSC71	4	BC007276	+
FTP3	5	P55795	+++
CLH1	6	D21260	+++
AKAP149	7	X97335	++
AES-1/2 / Groucho	8	U04241 AAD00654	+++

EXAMPLE 3: Characterization of FOXC2-interacting proteins

3.1. p621

p621 (SEQ ID NO:2; partial sequence) is a protein of unknown function that interacts with the Sp1 transcription factor (Gunther, M. et al. (2000) Mol. Cell. Biol. 210: 131-142). The mouse homologue, ATFa-associated factor (mAM), has recently been cloned and characterized (De Grave, F. et al. (2000) 19: 1807-1819). It acts as a

transcriptional co-repressor, and contains a bipartite NLS (Nuclear Localization Signal) and an ATPase activity.

In the present SRS screen, the interaction between FOXC2 and the p621 protein in yeast was supported by 12 obtained clones, comprising three different overlapping sequences. On basis of the identified fragments, the p621 region comprising nucleotides 580-1320 is sufficient for the FOXC2-p621 interaction.

3.2. NOLP

NOLP (for “nucleolar-localized protein”) is a nucleolar protein cloned from a human fetal brain cDNA library (Ueki, N. et al. (1998) Biochem. Biophys. Res. Comm. 252: 97-102). The NOLP gene encodes a 524-amino acid polypeptide with an *E. coli* helicase-homologous region, an acid-rich domain, three base-rich putative nuclear localization signals, a serine-rich region, and a coiled-coil domain. Northern blot analysis and RT-PCR revealed that NOLP is expressed as a 3.5-kb mRNA in fetal brain, adult brain, and testis. Deletion studies revealed that NOLP contains functional nuclear and nucleolar localization signals. In the present SRS screen, a single NOLP clone was identified, comprising a sequence that starts at the D145 residue of the NOLP sequence (SEQ ID NO:3).

3.3. Heat Shock Cognate Protein-71 (HSC71)

Heat Shock Cognate Protein-71 protein (HSC71; SEQ ID NO:4) has been recently identified from human brain tissues (GenBank Accession No. BC007276). The HSC71 protein contains a hsp70 domain (Pfam-PF00012; Bateman et al. (2002) Nucleic Acids Research 30:276-280) and it is possible to speculate that as other members of this hsp70 superfamily of proteins is involved in protein folding and assembling/disassembling of protein complexes. This has been suggested for the HSC71 protein isolated from rainbow trout (Zafarullah, M. et al. (1992) Eur. J. Biochem. 204: 893-900).

In the present SRS screen, nine HSC71 clones were obtained. They could be categorized into four different overlapping clones (from K₆₇ to the stop codon of HSC71 protein).

3.4. *FTP3*

FTP3 (SEQ ID NO:5) is a Heterogeneous Nuclear Ribonucleoprotein-H' (hnRNP-H'), and is ubiquitously expressed. It comprises three RNA-binding motifs and its function may include pre-mRNA processing and transport. hnRNPs are known to bind heterogeneous nuclear RNA, the transcripts produced by RNA polymerase II (Honoré, B. et al. (1995) J. Biol. Chem. 270: 28780-28789). In the present SRS screen, a single FTP3 clone was identified, corresponding to the C-terminal region of FTP3 (D348-A449).

3.5. *CLH1*

CLH1 (SEQ ID NO:6) is a human clathrin heavy chain protein. The clathrin heavy chain is the main structural protein of the cytoplasm surface of coated pits and vesicles, involved in receptor-mediated endocytosis, secretion and intracellular transfer of membrane-associated components. It is located at the cytoplasmic phase of coated pits and vesicles and it is readily expressed in most human adult tissues and localized to human chromosome 17 (Dodge, GR. et al. (1991) Genomics 1:174-178).

In the present SRS screen, 13 similar clones were identified, aligning at the N-terminal to N853 amino acid residue of the CLH1 sequence.

3.6. *AKAP149* (A Kinase Anchor Protein 149)

The effects of individual protein kinases (PKAs) isoforms are determined by their cellular localization, specified through binding to distinct A Kinase Anchor Proteins (AKAPs). AKAP149 (SEQ ID NO:7; Trendelenburg, G. et al. (1996) Biochem. Biophys. Res. Comm. 225: 313-319) is a putative splicing variant of S-AKAP84 (previously described by Lin et al. (1995) J. Biol. Chem. 270: 27804-27811; GenBank Accession No. U34074) with the important new feature of a RNA-binding motif (KH domain). Trendelenburg et al. showed that AKAP149 was expressed as a 4.2-kb transcript in all epithelial tissues examined, with the strongest signal being detected in prostate and small intestine RNAs. In addition, a 3.2-kb transcript was expressed exclusively in testis. Trendelenburg et al. speculated that AKAP149 is involved in the cAMP-dependent signal transduction pathway and in directing RNA to a specific cellular compartment.

In the present SRS screen, two clones were identified, both containing the entire CDS amino acid sequence of AKAP149.

3.7. *AES1-2/Groucho*

5 AES1-2/Groucho (SEQ ID NO:8) is a human protein exhibiting approximately 50% identity to the N-terminal region of *Drosophila* “enhancer of split Groucho” protein (Miyasaka, H. et al. (1993) Eur. J. Biochem. 216: 343-352). It is possibly involved in the negative regulation of proteins containing WD40 repeats. It has a nuclear localization and is expressed predominantly in muscle, heart and placenta. In the
10 present SRS screen, two clones were identified.

3.8. *Summary*

In summary, seven FOXC2-interacting proteins were isolated. Two of these proteins (p621 and AES1-2/*groucho*) are involved in transcription and could act by
15 repressing FOXC2 transcriptional activity. In addition, three cytoplasmic proteins (AKAP, Clathrin and HSC71) involved in cellular and matrix localization, and protein folding activity, were identified. Finally, two proteins of nuclear localization; one involved in RNA processing (FTP3) and one of unknown function (NOLP), were
20 identified.

EXAMPLE 4: Expression profiling of FOXC2-interacting proteins

To determine the tissue transcript expression profile for the FOXC2-interacting proteins described in Example 3, a computer analysis of Affymetrix chips containing human transcripts from adipose tissue, liver and muscle was performed.

25 PolyA+ mRNAs were extracted from human tissues from healthy patients using a Dynabeads mRNA Direct™ kit (DynaL A.S., Norway). White adipose, liver and muscle tissues were from biopsies. mRNAs were reverse transcribed using a T7-tagged oligo-dT primer and double-stranded cDNAs were generated. These cDNAs were then amplified and labeled using in vitro transcription (IVT) with T7 RNA polymerase and
30 biotinylated nucleotides. The populations of cRNAs obtained after IVT were purified and fragmented by heat to produce a distribution of RNA fragment sizes from approximately 35 to 200 bases. The Human Genome U95 Set of five GeneChip® probe arrays (Affymetrix; catalog Nos. 900303, 900305, 900307, 900309 and 900311) were

hybridized using the recommended buffer overnight at 45°C with the denatured cRNA samples. The arrays were then washed and stained with R-phycoerythrin streptavidin with the help of an Affymetrix fluidics station. The cartridges were scanned using a Hewlett-Packard confocal scanner and the images were analyzed with the GeneChip 4.1 software (Affymetrix). The identity of the genes represented on the probe arrays was assessed by performing searches using BLAST (Altschul et al. (1990) J. Mol. Biol. 215: 403-410) on available protein sequence databanks.

The results indicated that all identified FOXC2-interacting proteins are present in adipose and liver tissue, except for NOLP and clathrin proteins. In muscle, all identified FOXC2-interacting proteins are present except for NOLP. It can be concluded that the FOXC2-interacting proteins are expressed in tissues involved in energy metabolism and therefore putatively relevant to medical conditions relating to diabetes and obesity.

15 EXAMPLE 5: Co-immunoprecipitation

Co-immunoprecipitation of proteins from whole-cell extracts is a valuable approach to test for physical interactions between proteins of interest (Current Protocols in Molecular Biology, Chapter 20: Analysis of protein interactions, 2000, John Wiley & Sons, Inc. 2000). For instance, FOXC2 and each of the identified FOXC2-interacting proteins can be in vitro transcribed/translated under the control of T7 promoter in experiments using a TNT@Coupled Reticulocyte Lysate System (Promega, 2800 Woods Hollow Road, Madison-WI53711, USA) in the presence of ³⁵S-methionine. The FOXC2-hit complex can be immunoprecipitated using antibodies against FOXC2 or an epitope tag present in one of the proteins expressed as a tag-fusion protein (e.g. c-myc monoclonal or AH-polyclonal antibodies from Clontech). The complex can be resolved by SDS-PAGE. The subsequent exposure of the gel to an X-ray film or phosphorimaging screen can identify the presence of bands of expected size corresponding to the FOXC2-hit complex if these proteins interact to FOXC2.

30 EXAMPLE 6: Preparation of anti-FOXC2 antibodies

Antibodies are an important tool in the analysis of protein-protein interaction (see e.g. Current Protocols in Molecular Biology, Chapter 11: Immunology, John Wiley & Sons, Inc.). The human FOXC2 protein, or synthetic fragments of the FOXC2 sequence which are specific and antigenic, can be used to immunize animals such as

rabbits. Polyclonal antibodies can be raised following standard protocols (Antibodies, A laboratory Manual, Chapter 5: Immunizations, 1988, Harlow & Lane, CHS) and affinity purified from the whole sera when using peptides as antigen. The antibodies will be useful for co-immunoprecipitation of the FOXC2/FOXC2-interacting protein complex,

5 as well as for western blot analysis of the resolved complex.

CLAIMS

1. A substantially pure protein complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises the amino acid sequence of
5 SEQ ID NO:1 and the second polypeptide comprises the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7.
2. The protein complex of claim 1, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:2.
10
3. The protein complex of claim 1, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:3.
4. The protein complex of claim 1, wherein the second polypeptide comprises
15 the amino acid sequence of SEQ ID NO:4.
5. The protein complex of claim 1, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:5.
- 20 6. The protein complex of claim 1, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:6.
7. The protein complex of claim 1, wherein the second polypeptide comprises the amino acid sequence of SEQ ID NO:7.
25
8. A pharmaceutical composition comprising an amount of the protein complex of claim 1 effective for the treatment or prevention of a medical condition associated with FOXC2 expression or activity, and a pharmaceutically acceptable carrier.
- 30 9. A method of modulating FOXC2 expression or activity, the method comprising contacting a cell expressing FOXC2 with an amount of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7, or a nucleic acid encoding the polypeptide, sufficient to modulate the expression or activity of FOXC2 in the cell.

10. A method for the treatment or prophylaxis of a medical condition treatable by modulated FOXC2 activity, the method comprising administering to a patient in need of such treatment or prophylaxis an amount of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7 effective to treat or prevent a medical condition treatable by modulated FOXC2 activity, and a pharmaceutically acceptable carrier.

11. The method of claim 10, wherein the medical condition is treatable by increased FOXC2 activity.

12. The method of claim 11, wherein the medical condition is obesity, hypertriglyceridemia, diet-induced insulin resistance, or type 2 diabetes.

13. The method of claim 10, wherein the medical condition is treatable by decreased FOXC2 activity.

14. The method of claim 13, wherein the medical condition is anorexia.

15. A method of identifying an agent that modulates the formation of a FOXC2 protein complex, the method comprising:

(i) contacting a first polypeptide comprising the amino acid sequence of SEQ ID NO:1 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7, in the presence of a candidate agent;

(ii) measuring the formation of a complex between the first polypeptide and the second polypeptide in the presence of the candidate agent; and

(iii) comparing the formation of the complex between the first polypeptide and the second polypeptide in the presence of the candidate agent with the formation of a complex between the first polypeptide and the second polypeptide in the absence of the candidate agent,

to thereby determine whether the candidate agent modulates the formation of a FOXC2 protein complex.

16. A method of identifying an agent that modulates a FOXC2 activity, the method comprising:

(i) contacting a first polypeptide comprising the amino acid sequence of SEQ ID NO:1 and a second polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7 in the presence of a candidate agent;

(ii) measuring a FOXC2 activity of the first polypeptide in the presence of the candidate agent; and

(iii) comparing the FOXC2 activity of the first polypeptide in the presence of the candidate agent with the FOXC2 activity of the first polypeptide in the absence of the candidate agent,

to thereby determine whether the candidate agent modulates a FOXC2 activity.

17. A method of identifying an agent that modulates a FOXC2 activity, the method comprising:

(i) contacting a first polypeptide comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7 with a candidate agent;

(ii) determining that the candidate agent binds to the first polypeptide;

(iii) contacting a second polypeptide comprising the amino acid sequence of SEQ ID NO:1 with the candidate agent;

(iv) measuring a FOXC2 activity of the second polypeptide in the presence of the candidate agent; and

(v) comparing the FOXC2 activity of the second polypeptide in the presence of the candidate agent with the FOXC2 activity of the second polypeptide in the absence of the candidate agent,

to thereby determine whether the candidate agent modulates a FOXC2 activity.

18. A method for the treatment or prophylaxis of a medical condition treatable by modulated FOXC2 activity, the method comprising administering to a patient in need of such treatment or prophylaxis an amount of an agent identified by the method of claim 15 effective to treat or prevent a medical condition treatable by modulated FOXC2 activity, and a pharmaceutically acceptable carrier.

19. The method of claim 18, wherein the medical condition is treatable by increased FOXC2 activity.

20. The method of claim 19, wherein the medical condition is obesity, hypertriglyceridemia, diet-induced insulin resistance, or type 2 diabetes.

5 21. The method of claim 18, wherein the medical condition is treatable by decreased FOXC2 activity.

22. The method of claim 21, wherein the medical condition is anorexia.

10 23. A method for purifying a FOXC2-interacting protein, the method comprising:

- (i) contacting a protein complex comprising a FOXC2 protein comprising the amino acid sequence of SEQ ID NO:1 and a FOXC2-interacting protein comprising the amino acid sequence of SEQ ID NO:2, 3, 4, 5, 6, or 7 with an antibody that binds to the
15 protein complex; and
- (ii) purifying the FOXC2-interacting protein from the protein complex.

SEQUENCE LISTING

<110> Biovitrum AB

<120> Protein complexes

<130> BV-1012

<160> 12

<170> PatentIn version 3.0

<210> 1

<211> 501

<212> PRT

<213> human

<300>

<308> GenBank/Y08223

<309> 1997-05-14

<400> 1

Met Gln Ala Arg Tyr Ser Val Ser Asp Pro Asn Ala Leu Gly Val Val
 1 5 10 15

Pro Tyr Leu Ser Glu Gln Asn Tyr Tyr Arg Ala Ala Gly Ser Tyr Gly
 20 25 30

Gly Met Ala Ser Pro Met Gly Val Tyr Ser Gly His Pro Glu Gln Tyr
 35 40 45

Ser Ala Gly Met Gly Arg Ser Tyr Ala Pro Tyr His His His Gln Pro
 50 55 60

Ala Ala Pro Lys Asp Leu Val Lys Pro Pro Tyr Ser Tyr Ile Ala Leu
 65 70 75 80

Ile Thr Met Ala Ile Gln Asn Ala Pro Glu Lys Lys Ile Thr Leu Asn
 85 90 95

Gly Ile Tyr Gln Phe Ile Met Asp Arg Phe Pro Phe Tyr Arg Glu Asn
 100 105 110

Lys Gln Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu
 115 120 125

Cys Phe Val Lys Val Pro Arg Asp Asp Lys Lys Pro Gly Lys Gly Ser
 130 135 140

Tyr Trp Thr Leu Asp Pro Asp Ser Tyr Asn Met Phe Glu Asn Gly Ser
 145 150 155 160

Phe Leu Arg Arg Arg Arg Arg Phe Lys Lys Lys Asp Val Ser Lys Glu
 165 170 175

Lys Glu Glu Arg Ala His Leu Lys Glu Pro Pro Pro Ala Ala Ser Lys
 180 185 190

Gly Ala Pro Ala Thr Pro His Leu Ala Asp Ala Pro Lys Glu Ala Glu
 195 200 205
 Lys Lys Val Val Ile Lys Ser Glu Ala Ala Ser Pro Ala Leu Pro Val
 210 215 220
 Ile Thr Lys Val Glu Thr Leu Ser Pro Glu Ser Ala Leu Gln Gly Ser
 225 230 235 240
 Pro Arg Ser Ala Ala Ser Thr Pro Ala Gly Ser Pro Asp Gly Ser Leu
 245 250 255
 Pro Glu His His Ala Ala Ala Pro Asn Gly Leu Pro Gly Phe Ser Val
 260 265 270
 Glu Asn Ile Met Thr Leu Arg Thr Ser Pro Pro Gly Gly Glu Leu Ser
 275 280 285
 Pro Gly Ala Gly Arg Ala Gly Leu Val Val Pro Pro Leu Ala Leu Pro
 290 295 300
 Tyr Ala Ala Ala Pro Pro Ala Ala Tyr Gly Gln Pro Cys Ala Gln Gly
 305 310 315 320
 Leu Glu Ala Gly Ala Ala Gly Gly Tyr Gln Cys Ser Met Arg Ala Met
 325 330 335
 Ser Leu Tyr Thr Gly Ala Glu Arg Pro Ala His Met Cys Val Pro Pro
 340 345 350
 Ala Leu Asp Glu Ala Leu Ser Asp His Pro Ser Gly Pro Thr Ser Pro
 355 360 365
 Leu Ser Ala Leu Asn Leu Ala Ala Gly Gln Glu Gly Ala Leu Ala Ala
 370 375 380
 Thr Gly His His His Gln His His Gly His His His Pro Gln Ala Pro
 385 390 395 400
 Pro Pro Pro Pro Ala Pro Gln Pro Gln Pro Thr Pro Gln Pro Gly Ala
 405 410 415
 Ala Ala Ala Gln Ala Ala Ser Trp Tyr Leu Asn His Ser Gly Asp Leu
 420 425 430
 Asn His Leu Pro Gly His Thr Phe Ala Ala Gln Gln Gln Thr Phe Pro
 435 440 445
 Asn Val Arg Glu Met Phe Asn Ser His Arg Leu Gly Ile Glu Asn Ser
 450 455 460
 Thr Leu Gly Glu Ser Gln Val Ser Gly Asn Ala Ser Cys Gln Leu Pro
 465 470 475 480
 Tyr Arg Ser Thr Pro Pro Leu Tyr Arg His Ala Ala Pro Tyr Ser Tyr
 485 490 495
 Asp Cys Thr Lys Tyr
 500

<210> 2
 <211> 514
 <212> PRT
 <213> human

<300>
 <308> GenBank/AJ242978
 <309> 2000-09-10

<400> 2
 Pro Ser Glu Lys Asn Glu Phe Ser Arg Arg Lys Arg Ser Lys Ser Glu
 1 5 10 15
 Asp Met Asp Asn Val Gln Ser Lys Arg Arg Arg Tyr Met Glu Glu Glu
 20 25 30
 Tyr Glu Ala Glu Phe Gln Val Lys Ile Thr Ala Lys Gly Asp Ile Asn
 35 40 45
 Gln Lys Leu Gln Lys Val Ile Gln Trp Leu Leu Glu Glu Lys Leu Cys
 50 55 60
 Ala Leu Gln Cys Ala Val Phe Asp Lys Thr Leu Ala Glu Leu Lys Thr
 65 70 75 80
 Arg Val Glu Lys Ile Glu Cys Asn Lys Arg His Lys Thr Val Leu Thr
 85 90 95
 Glu Leu Gln Ala Lys Ile Ala Arg Leu Thr Lys Arg Phe Glu Ala Ala
 100 105 110
 Lys Glu Asp Leu Lys Lys Arg His Glu His Pro Pro Asn Pro Pro Val
 115 120 125
 Ser Pro Gly Lys Thr Val Asn Asp Val Asn Ser Asn Asn Asn Met Ser
 130 135 140
 Tyr Arg Asn Ala Gly Thr Val Arg Gln Met Leu Glu Ser Lys Arg Asn
 145 150 155 160
 Val Ser Glu Ser Ala Pro Pro Ser Phe Gln Thr Pro Val Asn Thr Val
 165 170 175
 Ser Ser Thr Asn Leu Val Thr Pro Pro Ala Val Val Ser Ser Gln Pro
 180 185 190
 Lys Leu Gln Thr Pro Val Thr Ser Gly Ser Leu Thr Ala Thr Ser Val
 195 200 205
 Leu Pro Ala Pro Asn Thr Ala Thr Val Val Ala Thr Thr Gln Val Pro
 210 215 220
 Ser Gly Asn Pro Gln Pro Thr Ile Ser Leu Gln Pro Leu Pro Val Ile
 225 230 235 240
 Leu His Val Pro Val Ala Val Ser Ser Gln Pro Gln Leu Leu Gln Ser
 245 250 255
 His Pro Gly Thr Leu Val Thr Asn Gln Pro Ser Gly Asn Val Glu Phe
 260 265 270


```

Ile Ser Val Gln Ser Pro Pro Thr Val Ser Gly Leu Thr Lys Asn Pro
    275                                280                                285

Val Ser Leu Pro Ser Leu Pro Asn Pro Thr Lys Pro Asn Asn Val Pro
    290                                295                                300

Ser Val Pro Ser Pro Ser Ile Gln Arg Asn Pro Thr Ala Ser Ala Ala
    305                                310                                315                                320

Pro Leu Gly Thr Thr Leu Ala Val Gln Ala Val Pro Thr Ala His Ser
    325                                330                                335

Ile Val Gln Ala Thr Arg Thr Ser Leu Pro Thr Val Gly Pro Ser Gly
    340                                345                                350

Leu Tyr Ser Pro Ser Thr Asn Arg Gly Pro Ile Gln Met Lys Ile Pro
    355                                360                                365

Ile Ser Ala Phe Ser Thr Ser Ser Ala Ala Glu Gln Asn Ser Asn Thr
    370                                375                                380

Thr Pro Arg Ile Glu Asn Gln Thr Asn Lys Thr Ile Asp Ala Ser Val
    385                                390                                395                                400

Ser Lys Lys Ala Ala Asp Ser Thr Ser Gln Cys Gly Lys Ala Thr Gly
    405                                410                                415

Ser Asp Ser Ser Gly Val Ile Asp Leu Thr Met Asp Asp Glu Glu Ser
    420                                425                                430

Gly Ala Ser Gln Asp Pro Lys Lys Leu Asn His Thr Pro Val Ser Thr
    435                                440                                445

Met Ser Ser Ser Gln Pro Val Ser Arg Pro Leu Gln Pro Ile Gln Pro
    450                                455                                460

Ala Pro Pro Leu Gln Pro Ser Gly Val Pro Thr Ser Gly Pro Ser Gln
    465                                470                                475                                480

Thr Thr Ile His Leu Leu Pro Thr Ala Pro Thr Thr Val Asn Val Thr
    485                                490                                495

His Arg Pro Val Thr Gln Val Thr Thr Arg Leu Pro Val Pro Arg Ala
    500                                505                                510

Pro Ala

```

<210> 3
 <211> 524
 <212> PRT
 <213> human

<300>
 <308> GenBank/AB017800
 <309> 1999-02-06

<400> 3
 Met His Val Glu Thr Gly Pro Asn Gly Glu Gln Ile Arg Lys His Ala
 1 5 10 15

Gly Gln Lys Arg Thr Tyr Lys Ala Ile Ser Glu Ser Tyr Ala Phe Leu
 20 25 30
 Pro Arg Glu Ala Val Thr Arg Phe Leu Met Ser Cys Ser Glu Cys Gln
 35 40 45
 Lys Arg Met His Leu Asn Pro Asp Gly Thr Asp His Lys Asp Asn Gly
 50 55 60
 Lys Pro Pro Thr Leu Val Thr Ser Met Ile Asp Tyr Asn Met Pro Ile
 65 70 75 80
 Thr Met Ala Tyr Met Lys His Met Lys Leu Gln Leu Leu Asn Ser Gln
 85 90 95
 Gln Asp Glu Asp Glu Ser Ser Ile Glu Ser Asp Glu Phe Asp Met Ser
 100 105 110
 Asp Ser Thr Arg Met Ser Ala Val Asn Ser Asp Leu Ser Ser Asn Leu
 115 120 125
 Glu Glu Arg Met Gln Ser Pro Gln Asn Leu His Gly Gln Gln Asp Asp
 130 135 140
 Asp Ser Ala Ala Glu Ser Phe Asn Gly Asn Glu Thr Leu Gly His Ser
 145 150 155 160
 Ser Ile Ala Ser Gly Gly Thr His Ser Arg Glu Met Gly Asp Ser Asn
 165 170 175
 Ser Asp Gly Lys Thr Gly Leu Glu Gln Asp Glu Gln Pro Leu Asn Leu
 180 185 190
 Ser Asp Ser Pro Leu Ser Ala Gln Leu Thr Ser Glu Tyr Arg Ile Asp
 195 200 205
 Asp His Asn Ser Asn Gly Lys Asn Lys Tyr Lys Asn Leu Leu Ile Ser
 210 215 220
 Asp Leu Lys Met Glu Arg Glu Ala Arg Glu Asn Gly Ser Lys Ser Pro
 225 230 235 240
 Ala His Ser Tyr Ser Ser Tyr Asp Ser Gly Lys Asn Glu Ser Val Asp
 245 250 255
 Arg Gly Ala Glu Asp Leu Ser Leu Asn Arg Gly Asp Glu Asp Glu Asp
 260 265 270
 Asp His Glu Asp His Asp Asp Ser Glu Lys Val Asn Glu Thr Asp Gly
 275 280 285
 Val Glu Ala Glu Arg Leu Lys Ala Phe Asn Met Phe Val Arg Leu Phe
 290 295 300
 Val Asp Glu Asn Leu Asp Arg Met Val Pro Ile Ser Lys Gln Pro Lys
 305 310 315 320
 Glu Lys Ile Gln Ala Ile Ile Asp Ser Cys Arg Arg Gln Phe Pro Glu
 325 330 335

Tyr Gln Glu Arg Ala Arg Lys Arg Ile Arg Thr Tyr Leu Lys Ser Cys
 340 345 350
 Arg Arg Met Lys Arg Ser Gly Phe Glu Met Ser Arg Pro Ile Pro Ser
 355 360 365
 His Leu Thr Ser Ala Val Ala Glu Ser Ile Leu Ala Ser Ala Cys Glu
 370 375 380
 Ser Glu Ser Arg Asn Ala Ala Lys Arg Met Arg Leu Glu Arg Gln Gln
 385 390 395 400
 Asp Glu Ser Ala Pro Ala Asp Lys Gln Cys Lys Pro Glu Ala Thr Gln
 405 410 415
 Ala Thr Tyr Ser Thr Ser Ala Val Pro Gly Ser Gln Asp Val Leu Tyr
 420 425 430
 Ile Asn Gly Asn Gly Thr Tyr Ser Tyr His Ser Tyr Arg Gly Leu Gly
 435 440 445
 Gly Gly Leu Leu Asn Leu Asn Asp Ala Ser Ser Ser Gly Pro Thr Asp
 450 455 460
 Leu Ser Met Lys Arg Gln Leu Ala Thr Ser Ser Gly Ser Ser Ser Ser
 465 470 475 480
 Ser Asn Ser Arg Pro Gln Leu Ser Pro Thr Glu Ile Asn Ala Val Arg
 485 490 495
 Gln Leu Val Ala Gly Tyr Arg Glu Ser Ala Ala Phe Leu Leu Arg Ser
 500 505 510
 Ala Asp Glu Leu Glu Asn Leu Ile Leu Gln Gln Asn
 515 520

<210> 4
 <211> 586
 <212> PRT
 <213> human

<300>
 <308> GenBank/BC007276
 <309> 2001-07-12

<400> 4
 Met Asn Pro Thr Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg
 1 5 10 15
 Arg Phe Asp Asp Ala Val Val Gln Ser Asp Met Lys His Trp Pro Phe
 20 25 30
 Met Val Val Asn Asp Ala Gly Arg Pro Lys Val Gln Val Glu Tyr Lys
 35 40 45
 Gly Glu Thr Lys Ser Phe Tyr Pro Glu Glu Val Ser Ser Met Val Leu
 50 55 60
 Thr Lys Met Lys Glu Ile Ala Glu Ala Tyr Leu Gly Lys Thr Val Thr
 65 70 75 80

Asn Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln
 85 90 95
 Ala Thr Lys Asp Ala Gly Thr Ile Ala Gly Leu Asn Val Leu Arg Ile
 100 105 110
 Ile Asn Glu Pro Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Lys Lys
 115 120 125
 Val Gly Ala Glu Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr
 130 135 140
 Phe Asp Val Ser Ile Leu Thr Ile Glu Asp Gly Ile Phe Glu Val Lys
 145 150 155 160
 Ser Thr Ala Gly Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg
 165 170 175
 Met Val Asn His Phe Ile Ala Glu Phe Lys Arg Lys His Lys Lys Asp
 180 185 190
 Ile Ser Glu Asn Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu
 195 200 205
 Arg Ala Lys Arg Thr Leu Ser Ser Ser Thr Gln Ala Ser Ile Glu Ile
 210 215 220
 Asp Ser Leu Tyr Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala
 225 230 235 240
 Arg Phe Glu Glu Leu Asn Ala Asp Leu Phe Arg Gly Thr Leu Asp Pro
 245 250 255
 Val Glu Lys Ala Leu Arg Asp Ala Lys Leu Asp Lys Ser Gln Ile His
 260 265 270
 Asp Ile Val Leu Val Gly Gly Ser Thr Arg Ile Pro Lys Ile Gln Lys
 275 280 285
 Leu Leu Gln Asp Phe Phe Asn Gly Lys Glu Leu Asn Lys Ser Ile Asn
 290 295 300
 Pro Asp Glu Ala Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu
 305 310 315 320
 Ser Gly Asp Lys Ser Glu Asn Val Gln Asp Leu Leu Leu Leu Asp Val
 325 330 335
 Thr Pro Leu Ser Leu Gly Ile Glu Thr Ala Gly Gly Val Met Thr Val
 340 345 350
 Leu Ile Lys Arg Asn Thr Thr Ile Pro Thr Lys Gln Thr Gln Thr Phe
 355 360 365
 Thr Thr Tyr Ser Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu
 370 375 380
 Gly Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu
 385 390 395 400

Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val
 405 410 415
 Thr Phe Asp Ile Asp Ala Asn Gly Ile Leu Asn Val Ser Ala Val Asp
 420 425 430
 Lys Ser Thr Gly Lys Glu Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly
 435 440 445
 Arg Leu Ser Lys Glu Asp Ile Glu Arg Met Val Gln Glu Ala Glu Lys
 450 455 460
 Tyr Lys Ala Glu Asp Glu Lys Gln Arg Asp Lys Val Ser Ser Lys Asn
 465 470 475 480
 Ser Leu Glu Ser Tyr Ala Phe Asn Met Lys Ala Thr Val Glu Asp Glu
 485 490 495
 Lys Leu Gln Gly Lys Ile Asn Asp Glu Asp Lys Gln Lys Ile Leu Asp
 500 505 510
 Lys Cys Asn Glu Ile Ile Asn Trp Leu Asp Lys Asn Gln Thr Ala Glu
 515 520 525
 Lys Glu Glu Phe Glu His Gln Gln Lys Glu Leu Glu Lys Val Cys Asn
 530 535 540
 Pro Ile Ile Thr Lys Leu Tyr Gln Ser Ala Gly Gly Met Pro Gly Gly
 545 550 555 560
 Met Pro Gly Gly Phe Pro Gly Gly Gly Ala Pro Pro Ser Gly Gly Ala
 565 570 575
 Ser Ser Gly Pro Thr Ile Glu Glu Val Asp
 580 585

<210> 5
 <211> 449
 <212> PRT
 <213> human

<300>
 <308> GenPept/P55795
 <309> 2001-08-20

<400> 5
 Met Met Leu Ser Thr Glu Gly Arg Glu Gly Phe Val Val Lys Val Arg
 1 5 10 15
 Gly Leu Pro Trp Ser Cys Ser Ala Asp Glu Val Met Arg Phe Phe Ser
 20 25 30
 Asp Cys Lys Ile Gln Asn Gly Thr Ser Gly Ile Arg Phe Ile Tyr Thr
 35 40 45
 Arg Glu Gly Arg Pro Ser Gly Glu Ala Phe Val Glu Leu Glu Ser Glu
 50 55 60
 Glu Glu Val Lys Leu Ala Leu Lys Lys Asp Arg Glu Thr Met Gly His
 65 70 75 80

Arg Tyr Val Glu Val Phe Lys Ser Asn Ser Val Glu Met Asp Trp Val
 85 90 95
 Leu Lys His Thr Gly Pro Asn Ser Pro Asp Thr Ala Asn Asp Gly Phe
 100 105 110
 Val Arg Leu Arg Gly Leu Pro Phe Gly Cys Ser Lys Glu Glu Ile Val
 115 120 125
 Gln Phe Phe Ser Gly Leu Glu Ile Val Pro Asn Gly Met Thr Leu Pro
 130 135 140
 Val Asp Phe Gln Gly Arg Ser Thr Gly Glu Ala Phe Val Gln Phe Ala
 145 150 155 160
 Ser Gln Glu Ile Ala Glu Lys Ala Leu Lys Lys His Lys Glu Arg Ile
 165 170 175
 Gly His Arg Tyr Ile Glu Ile Phe Lys Ser Ser Arg Ala Glu Val Arg
 180 185 190
 Thr His Tyr Asp Pro Pro Arg Lys Leu Met Ala Met Gln Arg Pro Gly
 195 200 205
 Pro Tyr Asp Arg Pro Gly Ala Gly Arg Gly Tyr Asn Ser Ile Gly Arg
 210 215 220
 Gly Ala Gly Phe Glu Arg Met Arg Arg Gly Ala Tyr Gly Gly Gly Tyr
 225 230 235 240
 Gly Gly Tyr Asp Asp Tyr Gly Gly Tyr Asn Asp Gly Tyr Gly Phe Gly
 245 250 255
 Ser Asp Arg Phe Gly Arg Asp Leu Asn Tyr Cys Phe Ser Gly Met Ser
 260 265 270
 Asp His Arg Tyr Gly Asp Gly Gly Ser Ser Phe Gln Ser Thr Thr Gly
 275 280 285
 His Cys Val His Met Arg Gly Leu Pro Tyr Arg Ala Thr Glu Asn Asp
 290 295 300
 Ile Tyr Asn Phe Phe Ser Pro Leu Asn Pro Met Arg Val His Ile Glu
 305 310 315 320
 Ile Gly Pro Asp Gly Arg Val Thr Gly Glu Ala Asp Val Glu Phe Ala
 325 330 335
 Thr His Glu Asp Ala Val Ala Ala Met Ala Lys Asp Lys Ala Asn Met
 340 345 350
 Gln His Arg Tyr Val Glu Leu Phe Leu Asn Ser Thr Ala Gly Thr Ser
 355 360 365
 Gly Gly Ala Tyr Asp His Ser Tyr Val Glu Leu Phe Leu Asn Ser Thr
 370 375 380
 Ala Gly Ala Ser Gly Gly Ala Tyr Gly Ser Gln Met Met Gly Gly Met
 385 390 395 400

Gly Leu Ser Asn Gln Ser Ser Tyr Gly Gly Pro Ala Ser Gln Gln Leu
 405 410 415

Ser Gly Gly Tyr Gly Gly Gly Tyr Gly Gly Gln Ser Ser Met Ser Gly
 420 425 430

Tyr Asp Gln Val Leu Gln Glu Asn Ser Ser Asp Tyr Gln Ser Asn Leu
 435 440 445

Ala

<210> 6
 <211> 1675
 <212> PRT
 <213> human

<300>
 <308> GenBank/D21260
 <309> 2001-10-06

<400> 6
 Met Ala Gln Ile Leu Pro Ile Arg Phe Gln Glu His Leu Gln Leu Gln
 1 5 10 15
 Asn Leu Gly Ile Asn Pro Ala Asn Ile Gly Phe Ser Thr Leu Thr Met
 20 25 30
 Glu Ser Asp Lys Phe Ile Cys Ile Arg Glu Lys Val Gly Glu Gln Ala
 35 40 45
 Gln Val Val Ile Ile Asp Met Asn Asp Pro Ser Asn Pro Ile Arg Arg
 50 55 60
 Pro Ile Ser Ala Asp Ser Ala Ile Met Asn Pro Ala Ser Lys Val Ile
 65 70 75 80
 Ala Leu Lys Ala Gly Lys Thr Leu Gln Ile Phe Asn Ile Glu Met Lys
 85 90 95
 Ser Lys Met Lys Ala His Thr Met Thr Asp Asp Val Thr Phe Trp Lys
 100 105 110
 Trp Ile Ser Leu Asn Thr Val Ala Leu Val Thr Asp Asn Ala Val Tyr
 115 120 125
 His Trp Ser Met Glu Gly Glu Ser Gln Pro Val Lys Met Phe Asp Arg
 130 135 140
 His Ser Ser Leu Ala Gly Cys Gln Ile Ile Asn Tyr Arg Thr Asp Ala
 145 150 155 160
 Lys Gln Lys Trp Leu Leu Leu Thr Gly Ile Ser Ala Gln Gln Asn Arg
 165 170 175
 Val Val Gly Ala Met Gln Leu Tyr Ser Val Asp Arg Lys Val Ser Gln
 180 185 190
 Pro Ile Glu Gly His Ala Ala Ser Phe Ala Gln Phe Lys Met Glu Gly
 195 200 205

Asn Ala Glu Glu Ser Thr Leu Phe Cys Phe Ala Val Arg Gly Gln Ala
 210 215 220
 Gly Gly Lys Leu His Ile Ile Glu Val Gly Thr Pro Pro Thr Gly Asn
 225 230 235 240
 Gln Pro Phe Pro Lys Lys Ala Val Asp Val Phe Phe Pro Pro Glu Ala
 245 250 255
 Gln Asn Asp Phe Pro Val Ala Met Gln Ile Ser Glu Lys His Asp Val
 260 265 270
 Val Phe Leu Ile Thr Lys Tyr Gly Tyr Ile His Leu Tyr Asp Leu Glu
 275 280 285
 Thr Gly Thr Cys Ile Tyr Met Asn Arg Ile Ser Gly Glu Thr Ile Phe
 290 295 300
 Val Thr Ala Pro His Glu Ala Thr Ala Gly Ile Ile Gly Val Asn Arg
 305 310 315 320
 Lys Gly Gln Val Leu Ser Val Cys Val Glu Glu Glu Asn Ile Ile Pro
 325 330 335
 Tyr Ile Thr Asn Val Leu Gln Asn Pro Asp Leu Ala Leu Arg Met Ala
 340 345 350
 Val Arg Asn Asn Leu Ala Gly Ala Glu Glu Leu Phe Ala Arg Lys Phe
 355 360 365
 Asn Ala Leu Phe Ala Gln Gly Asn Tyr Ser Glu Ala Ala Lys Val Ala
 370 375 380
 Ala Asn Ala Pro Lys Gly Ile Leu Arg Thr Pro Asp Thr Ile Arg Arg
 385 390 395 400
 Phe Gln Ser Val Pro Ala Gln Pro Gly Gln Thr Ser Pro Leu Leu Gln
 405 410 415
 Tyr Phe Gly Ile Leu Leu Asp Gln Gly Gln Leu Asn Lys Tyr Glu Ser
 420 425 430
 Leu Glu Leu Cys Arg Pro Val Leu Gln Gln Gly Arg Lys Gln Leu Leu
 435 440 445
 Glu Lys Trp Leu Lys Glu Asp Lys Leu Glu Cys Ser Glu Glu Leu Gly
 450 455 460
 Asp Leu Val Lys Ser Val Asp Pro Thr Leu Ala Leu Ser Val Tyr Leu
 465 470 475 480
 Arg Ala Asn Val Pro Asn Lys Val Ile Gln Cys Phe Ala Glu Thr Gly
 485 490 495
 Gln Val Gln Lys Ile Val Leu Tyr Ala Lys Lys Val Gly Tyr Thr Pro
 500 505 510
 Asp Trp Ile Phe Leu Leu Arg Asn Val Met Arg Ile Ser Pro Asp Gln
 515 520 525

Gly Gln Gln Phe Ala Gln Met Leu Val Gln Asp Glu Glu Pro Leu Ala
 530 535 540
 Asp Ile Thr Gln Ile Val Asp Val Phe Met Glu Tyr Asn Leu Ile Gln
 545 550 555 560
 Gln Cys Thr Ala Phe Leu Leu Asp Ala Leu Lys Asn Asn Arg Pro Ser
 565 570 575
 Glu Gly Pro Leu Gln Thr Arg Leu Leu Glu Met Asn Leu Met His Ala
 580 585 590
 Pro Gln Val Ala Asp Ala Ile Leu Gly Asn Gln Met Phe Thr His Tyr
 595 600 605
 Asp Arg Ala His Ile Ala Gln Leu Cys Glu Lys Ala Gly Leu Leu Gln
 610 615 620
 Arg Ala Leu Glu His Phe Thr Asp Leu Tyr Asp Ile Lys Arg Ala Val
 625 630 635 640
 Val His Thr His Leu Leu Asn Pro Glu Trp Leu Val Asn Tyr Phe Gly
 645 650 655
 Ser Leu Ser Val Glu Asp Ser Leu Glu Cys Leu Arg Ala Met Leu Ser
 660 665 670
 Ala Asn Ile Arg Gln Asn Leu Gln Ile Cys Val Gln Val Ala Ser Lys
 675 680 685
 Tyr His Glu Gln Leu Ser Thr Gln Ser Leu Ile Glu Leu Phe Glu Ser
 690 695 700
 Phe Lys Ser Phe Glu Gly Leu Phe Tyr Phe Leu Gly Ser Ile Val Asn
 705 710 715 720
 Phe Ser Gln Asp Pro Asp Val His Phe Lys Tyr Ile Gln Ala Ala Cys
 725 730 735
 Lys Thr Gly Gln Ile Lys Glu Val Glu Arg Ile Cys Arg Glu Ser Asn
 740 745 750
 Cys Tyr Asp Pro Glu Arg Val Lys Asn Phe Leu Lys Glu Ala Lys Leu
 755 760 765
 Thr Asp Gln Leu Pro Leu Ile Ile Val Cys Asp Arg Phe Asp Phe Val
 770 775 780
 His Asp Leu Val Leu Tyr Leu Tyr Arg Asn Asn Leu Gln Lys Tyr Ile
 785 790 795 800
 Glu Ile Tyr Val Gln Lys Val Asn Pro Ser Arg Leu Pro Val Val Ile
 805 810 815
 Gly Gly Leu Leu Asp Val Asp Cys Ser Glu Asp Val Ile Lys Asn Leu
 820 825 830
 Ile Leu Val Val Arg Gly Gln Phe Ser Thr Asp Glu Leu Val Ala Glu
 835 840 845

Val Glu Lys Arg Asn Arg Leu Lys Leu Leu Leu Pro Trp Leu Glu Ala
 850 855 860
 Arg Ile His Glu Gly Cys Glu Glu Pro Ala Thr His Asn Ala Leu Ala
 865 870 875 880
 Lys Ile Tyr Ile Asp Ser Asn Asn Asn Pro Glu Arg Phe Leu Arg Glu
 885 890 895
 Asn Pro Tyr Tyr Asp Ser Arg Val Val Gly Lys Tyr Cys Glu Lys Arg
 900 905 910
 Asp Pro His Leu Ala Cys Val Ala Tyr Glu Arg Gly Gln Cys Asp Leu
 915 920 925
 Glu Leu Ile Asn Val Cys Asn Glu Asn Ser Leu Phe Lys Ser Leu Ser
 930 935 940
 Arg Tyr Leu Val Arg Arg Lys Asp Pro Glu Leu Trp Gly Ser Val Leu
 945 950 955 960
 Leu Glu Ser Asn Pro Tyr Arg Arg Pro Leu Ile Asp Gln Val Val Gln
 965 970 975
 Thr Ala Leu Ser Glu Thr Gln Asp Pro Glu Glu Val Ser Val Thr Val
 980 985 990
 Lys Ala Phe Met Thr Ala Asp Leu Pro Asn Glu Leu Ile Glu Leu Leu
 995 1000 1005
 Glu Lys Ile Val Leu Asp Asn Ser Val Phe Ser Glu His Arg Asn
 1010 1015 1020
 Leu Gln Asn Leu Leu Ile Leu Thr Ala Ile Lys Ala Asp Arg Thr
 1025 1030 1035
 Arg Val Met Glu Tyr Ile Asn Arg Leu Asp Asn Tyr Asp Ala Pro
 1040 1045 1050
 Asp Ile Ala Asn Ile Ala Ile Ser Asn Glu Leu Phe Glu Glu Ala
 1055 1060 1065
 Phe Ala Ile Phe Arg Lys Phe Asp Val Asn Thr Ser Ala Val Gln
 1070 1075 1080
 Val Leu Ile Glu His Ile Gly Asn Leu Asp Arg Ala Tyr Glu Phe
 1085 1090 1095
 Ala Glu Arg Cys Asn Glu Pro Ala Val Trp Ser Gln Leu Ala Lys
 1100 1105 1110
 Ala Gln Leu Gln Lys Gly Met Val Lys Glu Ala Ile Asp Ser Tyr
 1115 1120 1125
 Ile Lys Ala Asp Asp Pro Ser Ser Tyr Met Glu Val Val Gln Ala
 1130 1135 1140
 Ala Asn Thr Ser Gly Asn Trp Glu Glu Leu Val Lys Tyr Leu Gln
 1145 1150 1155

Met	Ala	Arg	Lys	Lys	Ala	Arg	Glu	Ser	Tyr	Val	Glu	Thr	Glu	Leu
1160						1165					1170			
Ile	Phe	Ala	Leu	Ala	Lys	Thr	Asn	Arg	Leu	Ala	Glu	Leu	Glu	Glu
1175						1180					1185			
Phe	Ile	Asn	Gly	Pro	Asn	Asn	Ala	His	Ile	Gln	Gln	Val	Gly	Asp
1190						1195					1200			
Arg	Cys	Tyr	Asp	Glu	Lys	Met	Tyr	Asp	Ala	Ala	Lys	Leu	Leu	Tyr
1205						1210					1215			
Asn	Asn	Val	Ser	Asn	Phe	Gly	Arg	Leu	Ala	Ser	Thr	Leu	Val	His
1220						1225					1230			
Leu	Gly	Glu	Tyr	Gln	Ala	Ala	Val	Asp	Gly	Ala	Arg	Lys	Ala	Asn
1235						1240					1245			
Ser	Thr	Arg	Thr	Trp	Lys	Glu	Val	Cys	Phe	Ala	Cys	Val	Asp	Gly
1250						1255					1260			
Lys	Glu	Phe	Arg	Leu	Ala	Gln	Met	Cys	Gly	Leu	His	Ile	Val	Val
1265						1270					1275			
His	Ala	Asp	Glu	Leu	Glu	Glu	Leu	Ile	Asn	Tyr	Tyr	Gln	Asp	Arg
1280						1285					1290			
Gly	Tyr	Phe	Glu	Glu	Leu	Ile	Thr	Met	Leu	Glu	Ala	Ala	Leu	Gly
1295						1300					1305			
Leu	Glu	Arg	Ala	His	Met	Gly	Met	Phe	Thr	Glu	Leu	Ala	Ile	Leu
1310						1315					1320			
Tyr	Ser	Lys	Phe	Lys	Pro	Gln	Lys	Met	Arg	Glu	His	Leu	Glu	Leu
1325						1330					1335			
Phe	Trp	Ser	Arg	Val	Asn	Ile	Pro	Lys	Val	Leu	Arg	Ala	Ala	Glu
1340						1345					1350			
Gln	Ala	His	Leu	Trp	Ala	Glu	Leu	Val	Phe	Leu	Tyr	Asp	Lys	Tyr
1355						1360					1365			
Glu	Glu	Tyr	Asp	Asn	Ala	Ile	Ile	Thr	Met	Met	Asn	His	Pro	Thr
1370						1375					1380			
Asp	Ala	Trp	Lys	Glu	Gly	Gln	Phe	Lys	Asp	Ile	Ile	Thr	Lys	Val
1385						1390					1395			
Ala	Asn	Val	Glu	Leu	Tyr	Tyr	Arg	Ala	Ile	Gln	Phe	Tyr	Leu	Glu
1400						1405					1410			
Phe	Lys	Pro	Leu	Leu	Leu	Asn	Asp	Leu	Leu	Met	Val	Leu	Ser	Pro
1415						1420					1425			
Arg	Leu	Asp	His	Thr	Arg	Ala	Val	Asn	Tyr	Phe	Ser	Lys	Val	Lys
1430						1435					1440			
Gln	Leu	Pro	Leu	Val	Lys	Pro	Tyr	Leu	Arg	Ser	Val	Gln	Asn	His
1445						1450					1455			

Asn Asn Lys Ser Val Asn Glu Ser Leu Asn Asn Leu Phe Ile Thr
 1460 1465 1470
 Glu Glu Asp Tyr Gln Ala Leu Arg Thr Ser Ile Asp Ala Tyr Asp
 1475 1480 1485
 Asn Phe Asp Asn Ile Ser Leu Ala Gln Arg Leu Glu Lys His Glu
 1490 1495 1500
 Leu Ile Glu Phe Arg Arg Ile Ala Ala Tyr Leu Phe Lys Gly Asn
 1505 1510 1515
 Asn Arg Trp Lys Gln Ser Val Glu Leu Cys Lys Lys Asp Ser Leu
 1520 1525 1530
 Tyr Lys Asp Ala Met Gln Tyr Ala Ser Glu Ser Lys Asp Thr Glu
 1535 1540 1545
 Leu Ala Glu Glu Leu Leu Gln Trp Phe Leu Gln Glu Glu Lys Arg
 1550 1555 1560
 Glu Cys Phe Gly Ala Cys Leu Phe Thr Cys Tyr Asp Leu Leu Arg
 1565 1570 1575
 Pro Asp Val Val Leu Glu Thr Ala Trp Arg His Asn Ile Met Asp
 1580 1585 1590
 Phe Ala Met Pro Tyr Phe Ile Gln Val Met Lys Glu Tyr Leu Thr
 1595 1600 1605
 Lys Val Asp Lys Leu Asp Ala Ser Glu Ser Leu Arg Lys Glu Glu
 1610 1615 1620
 Glu Gln Ala Thr Glu Thr Gln Pro Ile Val Tyr Gly Gln Pro Gln
 1625 1630 1635
 Leu Met Leu Thr Ala Gly Pro Ser Val Ala Val Pro Pro Gln Ala
 1640 1645 1650
 Pro Phe Gly Tyr Gly Tyr Thr Ala Pro Pro Tyr Gly Gln Pro Gln
 1655 1660 1665
 Pro Gly Phe Gly Tyr Ser Met
 1670 1675

<210> 7
 <211> 903
 <212> PRT
 <213> human

<300>
 <308> GenBank/X97335
 <309> 1996-12-10

<400> 7
 Met Ala Ile Gln Phe Arg Ser Leu Phe Pro Leu Ala Leu Pro Gly Met
 1 5 10 15
 Leu Ala Leu Leu Gly Trp Trp Trp Phe Phe Ser Arg Lys Lys Gly His
 20 25 30

Val Ser Ser His Asp Glu Gln Gln Val Glu Ala Gly Ala Val Gln Leu
 35 40 45
 Arg Ala Asp Pro Ala Ile Lys Glu Pro Leu Pro Val Glu Asp Val Cys
 50 55 60
 Pro Lys Val Val Ser Thr Pro Pro Ser Val Thr Glu Pro Pro Glu Lys
 65 70 75 80
 Glu Leu Ser Thr Val Ser Lys Leu Pro Ala Glu Pro Pro Ala Leu Leu
 85 90 95
 Gln Thr His Pro Pro Cys Arg Arg Ser Glu Ser Ser Gly Ile Leu Pro
 100 105 110
 Asn Thr Thr Asp Met Arg Leu Arg Pro Gly Thr Arg Arg Asp Asp Ser
 115 120 125
 Thr Lys Leu Glu Leu Ala Leu Thr Gly Gly Glu Ala Lys Ser Ile Pro
 130 135 140
 Leu Glu Cys Pro Leu Ser Ser Pro Lys Gly Val Leu Phe Ser Ser Lys
 145 150 155 160
 Ser Ala Glu Val Cys Lys Gln Asp Ser Pro Phe Ser Arg Val Pro Arg
 165 170 175
 Lys Val Gln Pro Gly Tyr Pro Val Val Pro Ala Glu Lys Arg Ser Ser
 180 185 190
 Gly Glu Arg Ala Arg Glu Thr Gly Gly Ala Glu Gly Thr Gly Asp Ala
 195 200 205
 Val Leu Gly Glu Lys Val Leu Glu Glu Ala Leu Leu Ser Arg Glu His.
 210 215 220
 Val Leu Glu Leu Glu Asn Ser Lys Gly Pro Ser Leu Ala Ser Leu Glu
 225 230 235 240
 Gly Glu Glu Asp Lys Gly Lys Ser Ser Ser Ser Gln Val Val Gly Pro
 245 250 255
 Val Gln Glu Glu Glu Tyr Val Ala Glu Lys Leu Pro Ser Arg Phe Ile
 260 265 270
 Glu Ser Ala His Thr Glu Leu Ala Lys Asp Asp Ala Ala Pro Ala Pro
 275 280 285
 Pro Val Ala Asp Ala Lys Ala Gln Asp Arg Gly Val Glu Gly Glu Leu
 290 295 300
 Gly Asn Glu Glu Ser Leu Asp Arg Asn Glu Glu Gly Leu Asp Arg Asn
 305 310 315 320
 Glu Glu Gly Leu Asp Arg Asn Glu Glu Ser Leu Asp Arg Asn Glu Glu
 325 330 335
 Gly Leu Asp Arg Asn Glu Glu Ile Lys Arg Ala Ala Phe Gln Ile Ile
 340 345 350

Ser Gln Val Ile Ser Glu Ala Thr Glu Gln Val Leu Ala Thr Thr Val
 355 360 365
 Gly Lys Val Ala Gly Arg Val Cys Gln Ala Ser Gln Leu Gln Gly Gln
 370 375 380
 Lys Glu Glu Ser Cys Val Pro Val His Gln Lys Thr Val Leu Gly Pro
 385 390 395 400
 Asp Thr Ala Glu Pro Ala Thr Ala Glu Ala Ala Val Ala Pro Pro Asp
 405 410 415
 Ala Gly Leu Pro Leu Pro Gly Leu Pro Ala Glu Gly Ser Pro Pro Pro
 420 425 430
 Lys Thr Tyr Val Ser Cys Leu Lys Ser Leu Leu Ser Ser Pro Thr Lys
 435 440 445
 Asp Ser Lys Pro Asn Ile Ser Ala His His Ile Ser Leu Ala Ser Cys
 450 455 460
 Leu Ala Leu Thr Thr Pro Ser Glu Glu Leu Pro Asp Arg Ala Gly Ile
 465 470 475 480
 Leu Val Glu Asp Ala Thr Cys Val Thr Cys Met Ser Asp Ser Ser Gln
 485 490 495
 Ser Val Pro Leu Val Ala Ser Pro Gly His Cys Ser Asp Ser Phe Ser
 500 505 510
 Thr Ser Gly Leu Glu Asp Ser Cys Thr Glu Thr Ser Ser Ser Pro Arg
 515 520 525
 Asp Lys Ala Ile Thr Pro Pro Leu Pro Glu Ser Thr Val Pro Phe Ser
 530 535 540
 Asn Gly Val Leu Lys Gly Glu Leu Ser Asp Leu Gly Ala Glu Asp Gly
 545 550 555 560
 Trp Thr Met Asp Ala Glu Ala Asp His Ser Gly Gly Ser Asp Arg Asn
 565 570 575
 Ser Met Asp Ser Val Asp Ser Cys Cys Ser Leu Lys Lys Thr Glu Ser
 580 585 590
 Phe Gln Asn Ala Gln Ala Gly Ser Asn Pro Lys Lys Val Asp Leu Ile
 595 600 605
 Ile Trp Glu Ile Glu Val Pro Lys His Leu Val Gly Arg Leu Ile Gly
 610 615 620
 Lys Gln Gly Arg Tyr Val Ser Phe Leu Lys Gln Thr Ser Gly Ala Lys
 625 630 635 640
 Ile Tyr Ile Ser Thr Leu Pro Tyr Thr Gln Ser Val Gln Ile Cys His
 645 650 655
 Ile Glu Gly Ser Gln His His Val Asp Lys Ala Leu Asn Leu Ile Gly
 660 665 670

Lys Lys Phe Lys Glu Leu Asn Leu Thr Asn Ile Tyr Ala Pro Pro Leu
 675 680 685
 Pro Ser Leu Ala Leu Pro Ser Leu Pro Met Thr Ser Trp Leu Met Leu
 690 695 700
 Pro Asp Gly Ile Thr Val Glu Val Ile Val Val Asn Gln Val Asn Ala
 705 710 715 720
 Gly His Leu Phe Val Gln Gln His Thr His Pro Thr Phe His Ala Leu
 725 730 735
 Arg Ser Leu Asp Gln Gln Met Tyr Leu Cys Tyr Ser Gln Pro Gly Ile
 740 745 750
 Pro Thr Leu Pro Thr Pro Val Glu Ile Thr Val Ile Cys Ala Ala Pro
 755 760 765
 Gly Ala Asp Gly Ala Trp Trp Arg Ala Gln Val Val Ala Ser Tyr Glu
 770 775 780
 Glu Thr Asn Glu Val Glu Ile Arg Tyr Val Asp Tyr Gly Gly Tyr Lys
 785 790 795 800
 Arg Val Lys Val Asp Val Leu Arg Gln Ile Arg Ser Asp Phe Val Thr
 805 810 815
 Leu Pro Phe Gln Gly Ala Glu Val Leu Leu Asp Ser Val Met Pro Leu
 820 825 830
 Ser Asp Asp Asp Gln Phe Ser Pro Glu Ala Asp Ala Ala Met Ser Glu
 835 840 845
 Met Thr Gly Asn Thr Ala Leu Leu Ala Gln Val Thr Ser Tyr Ser Pro
 850 855 860
 Thr Gly Leu Pro Leu Ile Gln Leu Trp Ser Val Val Gly Asp Glu Val
 865 870 875 880
 Val Leu Ile Asn Arg Ser Leu Val Glu Arg Gly Leu Ala Gln Trp Val
 885 890 895
 Asp Ser Tyr Tyr Thr Ser Leu
 900

<210> 8
 <211> 197
 <212> PRT
 <213> human

<300>
 <308> GenPept/AAD00654
 <309> 1999-01-05

<400> 8
 Met Met Phe Pro Gln Ser Arg His Ser Gly Ser Ser His Leu Pro Gln
 1 5 10 15
 Gln Leu Lys Phe Thr Thr Ser Asp Ser Cys Asp Arg Ile Thr Asp Glu
 20 25 30

Phe	Gln	Leu	Leu	Gln	Ala	Gln	Tyr	His	Ser	Leu	Lys	Leu	Glu	Cys	Asp	
		35						40				45				
Lys	Leu	Ala	Ser	Glu	Lys	Ser	Glu	Met	Gln	Arg	His	Tyr	Val	Met	Tyr	
		50						55				60				
Tyr	Glu	Met	Ser	Tyr	Gly	Leu	Asn	Ile	Glu	Met	His	Lys	Gln	Ala	Glu	
65					70					75					80	
Ile	Val	Lys	Arg	Leu	Asn	Gly	Ile	Cys	Ala	Gln	Val	Leu	Pro	Tyr	Leu	
		85						90					95			
Ser	Gln	Glu	His	Gln	Gln	Gln	Val	Leu	Gly	Ala	Ile	Glu	Arg	Ala	Lys	
		100						105					110			
Gln	Val	Thr	Ala	Pro	Glu	Leu	Asn	Ser	Ile	Ile	Arg	Gln	Gln	Leu	Gln	
		115						120					125			
Ala	His	Gln	Leu	Ser	Gln	Leu	Gln	Ala	Leu	Ala	Leu	Pro	Leu	Thr	Pro	
		130						135					140			
Leu	Pro	Val	Gly	Leu	Gln	Pro	Pro	Ser	Leu	Pro	Ala	Val	Ser	Ala	Gly	
145					150					155					160	
Thr	Gly	Leu	Leu	Ser	Leu	Ser	Ala	Leu	Gly	Ser	Gln	Ala	His	Leu	Ser	
		165						170					175			
Lys	Glu	Asp	Lys	Asn	Gly	His	Asp	Gly	Asp	Thr	His	Gln	Glu	Asp	Asp	
		180						185					190			
Gly	Glu	Lys	Ser	Asp												
		195														

```
<210> 9
<211> 33
<212> DNA
<213> Artificial
```

<220>
<223> PCR primer

<400> 9
cqcqgcatccc catgcaggcg cgctactccg tgt

33

```
<210> 10
<211> 33
<212> DNA
<213> Artificial
```

<220>
<223> PCR primer

<400> 10
cqcqqatcct cagtatttcg tgcagtcgta gga

33

$\langle 210 \rangle$	11
$\langle 211 \rangle$	20

<212> DNA
<213> Artificial

<220>
<223> PCR primer

<400> 11
taatacgact cactataggg

20

<210> 12
<211> 19
<212> DNA
<213> Artificial

<220>
<223> PCR primer

<400> 12
agggcgtgaa tgtaagcgt

19

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/47, A61K 38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 0227008 A1 (BIOVITRUM AB), 4 April 2002 (04.04.02) --	1-23
A	Genes & Development, Volume 15, 2001, Tsutomu Kume et al: "The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis", pages 2470-2482, see page 2479, right column, lines 7-119 --	1-23
A	Cell, Volume 106, September 7, 2001, Anna Cederberg et al: "FOX2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance", pages 563-573 --	1-23

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 11 April 2003	Date of mailing of the international search report 29-04-2003
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer YVONNE SIÖSTEEN/BS Telephone No. +46 8 782 25 00

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9854216 A1 (PHARMACIA & UPJOHN AB), 3 December 1998 (03.12.98) --	1-23
A	J. Mol. Biol. Volume 296, 2000, Maria J. P. Van Dongen et al: "Solution Structure and Dynamics of the DNA-binding Domain of the Adipocyte- transcription Factor FREAC-11, pages 351-359 --	1-23
A	WO 0160853 A1 (PHARMACIA AB), 23 August 2001 (23.08.01) -- -----	1-23

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/83/00139**Box I** Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: **9-14 and 18-22**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Claims 9-14 and 18-22 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule. 39.1.(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

29/03/03

International application No.

PCT/SE 03/00139

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0227008	A1	04/04/02	AU	9248101 A	08/04/02
				SE	0003435 D	00/00/00
				US	2002090707 A	11/07/02
				SE	0004102 D	00/00/00

WO	9854216	A1	03/12/98	AU	742500 B	03/01/02
				AU	7682698 A	30/12/98
				AU	7875698 A	17/07/98
				DE	69715245 D	00/00/00
				EP	0946914 A,B	06/10/99
				EP	1003776 A	31/05/00
				JP	2001507149 T	29/05/01
				JP	2002503102 T	29/01/02
				NO	995786 A	25/01/00
				NZ	501804 A	28/06/02
				SE	9701963 D	00/00/00

WO	0160853	A1	23/08/01	AU	3259901 A	27/08/01
				AU	3992200 A	09/10/00
				EP	1255774 A	13/11/02
				NO	20023709 A	17/10/02
				SE	0000531 D	00/00/00
				AU	1068701 A	23/04/01
				SE	0001982 D	00/00/00
				SE	0004629 D	00/00/00
